Picture loading failed.

Anti-CSF2 therapeutic antibody (Pre-made Namilumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Namilumab (alternative identifier MT203) is a human monoclonal antibody (class IgG1 kappa) that targets granulocyte macrophage-colony stimulating factor (GM-CSF)/colony stimulating factor 2 (CSF2) and is currently being researched for application in rheumatoid arthritis (RA) and psoriatic arthritis. Clinical trials investigating the therapeutic utility of Namilumab have include phase I and phase II clinical trials to establish the safety, tolerability and preliminary therapeutic utility of the antibody in plaque psoriasis and rheumatoid arthritis.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-362-1mg 1mg 3090
GMP-Bios-ab-362-10mg 10mg 21890
GMP-Bios-ab-362-100mg 100mg 148000
GMP-Bios-ab-362-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CSF2 therapeutic antibody (Pre-made Namilumab biosimilar,Whole mAb)
INN Name Namilumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesMicromet Inc;Izana Bioscience;Takeda Pharmaceuticals International GmbH
Conditions Approvedna
Conditions ActiveAnkylosing spondylitis;COVID-19
Conditions DiscontinuedPlaque psoriasis;Rheumatoid arthritis
Development TechHuman Phage Display